Abstract
Switching from Allopurinol to Febuxostat: A Comparison of The Rate of Renal Functional Decline in Patients With Moderate and Severe Chronic Kidney Disease
Highlights
Hyperuricemia has been reported to be related to the rapid progression of the renal functional decline in patients with chronic kidney disease (CKD) [1]
There was no significant difference in the rate of renal functional decline (ΔeGFR: Δestimated glemerular filtration rate) in any group; the rate after the switch tended to be decreased in comparison to before the switch
Oxypurinol is predominantly excreted by the kidney; the risk of adverse events is higher in CKD patients. febuxostat is a novel xanthine oxidase (XO) inhibitor that became clinically available in Japan in 2011
Summary
Hyperuricemia has been reported to be related to the rapid progression of the renal functional decline in patients with chronic kidney disease (CKD) [1]. Allopurinol reduces the uric acid concentration by acting as a xanthine oxidase (XO) inhibitor. Allopurinol is metabolized by XO and aldehyde oxidase and to oxypurinol, which is a XO inhibitor. It was reported that febuxostat was safe and effective in patients with moderate to severe kidney dysfunction [2], few studies have examined the usefulness of switching from allopurinol to febuxostat in advanced CKD patients. The aim of the present study was to clarify the effects of the rate of renal functional decline and other factors in patients with moderate to severe renal dysfunction who switched from allopurinol to febuxostat
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Biomedical Journal of Scientific & Technical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
